文献速递胸部肿瘤头颈与中枢神经肿瘤

BLU-667精准靶向RET驱动癌症

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
PubMed 文献 · Cancer Discov · 2018-04-15

RET是NSCLC、MTC和甲状腺乳头状癌的致癌驱动基因,现有MKI疗效有限且脱靶毒性大。BLU-667是高选择性RET抑制剂,体外强效抑制RET变异和耐药突变,体内抑制RET驱动肿瘤生长,首次人体试验中显著抑制RET信号并诱导持久缓解,无显著脱靶毒性。

要点

  • BLU-667对RET变异和耐药突变的效力是已批准MKI的10倍以上。
  • 体内抑制RET突变/融合驱动的NSCLC和甲状腺癌移植瘤生长,不抑制VEGFR2。
  • 首次人体试验中在RET变异NSCLC和MTC患者中诱导持久临床缓解,脱靶毒性不显著。

核心结论

  • BLU-667是强效选择性RET抑制剂,临床验证了选择性靶向RET的可行性。

研究设计与样本

  • 临床前体外和体内研究,以及首次人体试验。

主要发现

  • 体外对致癌RET变异和耐药突变效力较已批准MKI提高≥10倍。
  • 体内抑制多种RET突变和融合驱动的NSCLC和甲状腺癌移植瘤生长,未抑制VEGFR2。
  • 首次人体试验中显著抑制RET信号,在RET变异NSCLC和MTC患者中诱导持久临床缓解,无显著脱靶毒性。

临床怎么用

  • 对于RET驱动的NSCLC和MTC,BLU-667可能提供高选择性靶向治疗并减少脱靶毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer. No approved therapies have been designed to target RET; treatment has been limited to multikinase inhibitors (MKI), which can have significant off-target toxicities and limited efficacy. BLU-667 is a highly potent and selective RET inhibitor designed to overcome these limitations. In vitro, BLU-667 demonstrated ≥10-fold increased potency over approved MKIs against oncogenic RET variants and resistance mutants. In vivo, BLU-667 potently inhibited growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting VEGFR2. In first-in-human testing, BLU-667 significantly inhibited RET signaling and induced durable clinical responses in patients with RET-altered NSCLC and MTC without notable off-target toxicity, providing clinical validation for selective RET targeting.Significance: Patients with RET-driven cancers derive limited benefit from available MKIs. BLU-667 is a potent and selective RET inhibitor that induces tumor regression in cancer models with RET mutations and fusions. BLU-667 attenuated RET signaling and produced durable clinical responses in patients with RET-altered tumors, clinically validating selective RET targeting. Cancer Discov; 8(7); 836-49. ©2018 AACR.See related commentary by Iams and Lovly, p. 797This article is highlighted in the In This Issue feature, p. 781.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Subbiah V, Gainor JF, Rahal R, et al. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018. PMID: 29657135. doi:10.1158/2159-8290.CD-18-0338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。